Journal article
Molecular and Pathology Features of Colorectal Tumors and Patient Outcomes Are Associated with Fusobacterium nucleatum and Its Subspecies animalis
I Borozan, SH Zaidi, TA Harrison, AI Phipps, J Zheng, S Lee, QM Trinh, RS Steinfelder, J Adams, BL Banbury, SI Berndt, S Brezina, DD Buchanan, S Bullman, Y Cao, AB Farris, JC Figueiredo, M Giannakis, LE Heisler, JL Hopper Show all
Cancer Epidemiology Biomarkers and Prevention | Published : 2022
Abstract
Background: Fusobacterium nucleatum (F. nucleatum) activates oncogenic signaling pathways and induces inflammation to promote colorectal carcinogenesis. Methods: We characterized F. nucleatum and its subspecies in colorectal tumors and examined associations with tumor characteristics and colorectal cancer-specific survival. We conducted deep sequencing of nusA, nusG, and bacterial 16s rRNA genes in tumors from 1,994 patients with colorectal cancer and assessed associations between F. nucleatum presence and clinical characteristics, colorectal cancer-specific mortality, and somatic mutations. Results: F. nucleatum, which was present in 10.3% of tumors, was detected in a higher proportion of r..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
GECCO is supported in part by NCI/NIH awards U01 CA137088 (NCI, U. Peters), U01 CA164930 (NCI, U. Peters), and R01 CA176272 (NCI, P.A. Newcomb and A.T. Chan). The CCFR is supported in part by NIH/NCI awards U01 CA167551 (NCI, M.A. Jenkins), U01 CA074794 (NCI, P.A. Newcomb), U24 CA074794 (NCI, P.A. Newcomb), and R01 CA076366 (NCI, P.A. Newcomb). OFCCR is supported by U01 CA074783 (S. Gallinger), U24 CA074783 (S. Gallinger), and the Ontario Research Fund GL201-043 (B.W. Zanke). American Cancer Society funds the creation, maintenance, and update of the CPS-II cohort. CORSA: "_Osterreichische Nationalbank Jubil_aumsfondsprojekt" 12511 (A. Gsur) and Austrian Research Funding Agency (FFG) grant 829675 (A. Gsur). S. Ogino was supported by NCI (R35 CA197735), a Nodal Award from Dana-Farber Harvard Cancer Center, and Cancer Research UK Grand Challenge Award (through the OPTIMISTICC Team). M. Giannakis was supported by the Cancer ResearchUKGrand Challenge Award and a Stand Up to Cancer Colorectal Cancer Dream Team Translational Research Grant (SU2C-AACR-DT22-17). D.D. Buchanan is supported by an NHMRC R.D. Wright Career Development Fellowship. Additional funding was provided by the Ontario Institute for Cancer Research. We thank all those who agreed to participate in the CORSA study, including the patients and the control persons, as well as all the physicians and students. The authors thank the CPS-II participants and Study Management Group for their invaluable contributions to this research. The authors would also like to acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention National Program of Cancer Registries, and cancer registries supported by the National Cancer Institute Surveillance, Epidemiology and End Results program. The authors would like to thank all those at the GECCO Coordinating Center for helping bring together the data and people that made this project possible.